Cardiome Pharma (CRME) Misses Q2 EPS by 18c

Cardiome Pharma (NASDAQ: CRME) reported Q2 EPS of ($0.37), $0.18 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)